Prot #1289.6: A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment period in patients with schizophrenia on stable ant

Project: Research project

Project Details

Effective start/end date1/29/151/29/18


  • DrugDev Inc. (Prot #1289.6)
  • Boehringer Ingelheim Pharmaceuticals, Inc. (Prot #1289.6)